Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 217

1.

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.

Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman ID, Mise BP, Tomic S.

Diagn Pathol. 2013 Feb 6;8:21. doi: 10.1186/1746-1596-8-21.

PMID:
23388101
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Molecular characterization of 103 ovarian serous and mucinous tumors.

Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E.

Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8. Epub 2010 Dec 7.

PMID:
21136228
[PubMed - indexed for MEDLINE]
3.

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.

Clin Cancer Res. 2004 Oct 1;10(19):6432-6.

PMID:
15475429
[PubMed - indexed for MEDLINE]
Free Article
4.

An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.

O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG.

Am J Surg Pathol. 2005 Aug;29(8):1034-41.

PMID:
16006797
[PubMed - indexed for MEDLINE]
5.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

PMID:
24549645
[PubMed - indexed for MEDLINE]
Free PMC Article
6.
7.

The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.

Bar JK, Grelewski P, Noga L, Rabczyński J, Gryboś M, Jeleń M.

Adv Clin Exp Med. 2012 Jan-Feb;21(1):35-42.

PMID:
23214297
[PubMed - indexed for MEDLINE]
Free Article
8.

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Nodin B, Zendehrokh N, Sundström M, Jirström K.

Diagn Pathol. 2013 Jun 25;8:106. doi: 10.1186/1746-1596-8-106.

PMID:
23800114
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
[PubMed - indexed for MEDLINE]
10.

Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.

Cho YH, Kim DY, Kim JH, Kim YM, Kim KR, Nam JH, Kim YT.

Yonsei Med J. 2009 Apr 30;50(2):266-72. doi: 10.3349/ymj.2009.50.2.266.

PMID:
19430562
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

PMID:
24307542
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ; AOCS Study Group, deFazio A, Chenevix-Trench G, Bowtell DD.

Mol Cancer Res. 2008 Nov;6(11):1678-90. doi: 10.1158/1541-7786.MCR-08-0193.

PMID:
19010816
[PubMed - indexed for MEDLINE]
Free Article
13.

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2005 Feb;29(2):218-24.

PMID:
15644779
[PubMed - indexed for MEDLINE]
14.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Vang R, Shih IeM, Kurman RJ.

Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.

PMID:
19700937
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.

Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD.

Mod Pathol. 2013 Jun;26(6):825-34. doi: 10.1038/modpathol.2012.240. Epub 2013 Jan 25.

PMID:
23348904
[PubMed - indexed for MEDLINE]
Free Article
16.

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K.

Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18.

PMID:
19018267
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.

Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A.

Diagn Pathol. 2012 Sep 20;7:124. doi: 10.1186/1746-1596-7-124.

PMID:
22995373
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.

Lee SH, Kim H, Kim WY, Han HS, Lim SD, Kim WS, Kim S, Hwang TS.

Pathol Int. 2013 May;63(5):252-9. doi: 10.1111/pin.12060.

PMID:
23714252
[PubMed - indexed for MEDLINE]
19.

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.

Hum Pathol. 2013 Mar;44(3):329-35. doi: 10.1016/j.humpath.2012.07.010. Epub 2012 Oct 22.

PMID:
23089489
[PubMed - indexed for MEDLINE]
20.

Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.

Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack B, Sommer H, Friese K.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1047-55. Epub 2007 Apr 12.

PMID:
17433065
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk